FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894495537> ?p ?o ?g. }

• W2894495537 endingPage "1224" @default.
• W2894495537 startingPage "1217" @default.
• W2894495537 abstract "Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of participants and implications for caregivers.Four hundred and one adults aged 50 years or older received single RZV doses at 0 and 2 months in this open-label, single-arm, multicenter study (NCT02979639). Change in mean SF-36 Physical Functioning score following first-dose administration, quality of life, reactogenicity, safety, productivity loss, and health care resource utilization was assessed. The current analysis was performed post-vaccine dose-1; safety follow-up will continue until 1 year post-dose-2.The most common solicited local symptoms were injection-site pain (77.5%), redness (23.0%), and swelling (13.3%); the most frequent solicited systemic reactions were fatigue (33.5%), headache (28.3%), and myalgia (26.8%). Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed (mean +1.9 points, primary end point), and no overall quality-adjusted-life-year loss was recorded post-dose-1. Five participants reported lost workdays; caregiver workload was not increased.Overall, the physical functioning and quality of life of older adults were not affected by a first RZV dose. The observed reactogenicity was consistent with previous studies." @default.
• W2894495537 created "2018-10-05" @default.
• W2894495537 creator A5009725215 @default.
• W2894495537 creator A5012207802 @default.
• W2894495537 creator A5015731103 @default.
• W2894495537 creator A5028867550 @default.
• W2894495537 creator A5032891220 @default.
• W2894495537 creator A5034478332 @default.
• W2894495537 creator A5039067471 @default.
• W2894495537 creator A5051264386 @default.
• W2894495537 creator A5051875406 @default.
• W2894495537 creator A5051915476 @default.
• W2894495537 creator A5052604055 @default.
• W2894495537 creator A5061217494 @default.
• W2894495537 creator A5065562779 @default.
• W2894495537 creator A5084123217 @default.
• W2894495537 creator A5084194739 @default.
• W2894495537 date "2018-09-25" @default.
• W2894495537 modified "2023-10-13" @default.
• W2894495537 title "The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial" @default.
• W2894495537 cites W1868327112 @default.
• W2894495537 cites W1964914124 @default.
• W2894495537 cites W1991129383 @default.
• W2894495537 cites W1996464306 @default.
• W2894495537 cites W2008775818 @default.
• W2894495537 cites W2010207831 @default.
• W2894495537 cites W2013733406 @default.
• W2894495537 cites W2022877567 @default.
• W2894495537 cites W2027886016 @default.
• W2894495537 cites W2028419511 @default.
• W2894495537 cites W2071589319 @default.
• W2894495537 cites W2082084705 @default.
• W2894495537 cites W2089973119 @default.
• W2894495537 cites W2137654125 @default.
• W2894495537 cites W2138068778 @default.
• W2894495537 cites W2151572628 @default.
• W2894495537 cites W2482786872 @default.
• W2894495537 cites W2519957152 @default.
• W2894495537 cites W2569903330 @default.
• W2894495537 cites W2580539158 @default.
• W2894495537 cites W2624880999 @default.
• W2894495537 cites W2734800292 @default.
• W2894495537 cites W2734980347 @default.
• W2894495537 cites W2765537391 @default.
• W2894495537 doi "https://doi.org/10.1093/gerona/gly218" @default.
• W2894495537 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6625580" @default.
• W2894495537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30256905" @default.
• W2894495537 hasPublicationYear "2018" @default.
• W2894495537 type Work @default.
• W2894495537 sameAs 2894495537 @default.
• W2894495537 citedByCount "16" @default.
• W2894495537 countsByYear W28944955372019 @default.
• W2894495537 countsByYear W28944955372020 @default.
• W2894495537 countsByYear W28944955372021 @default.
• W2894495537 countsByYear W28944955372022 @default.
• W2894495537 countsByYear W28944955372023 @default.
• W2894495537 crossrefType "journal-article" @default.
• W2894495537 hasAuthorship W2894495537A5009725215 @default.
• W2894495537 hasAuthorship W2894495537A5012207802 @default.
• W2894495537 hasAuthorship W2894495537A5015731103 @default.
• W2894495537 hasAuthorship W2894495537A5028867550 @default.
• W2894495537 hasAuthorship W2894495537A5032891220 @default.
• W2894495537 hasAuthorship W2894495537A5034478332 @default.
• W2894495537 hasAuthorship W2894495537A5039067471 @default.
• W2894495537 hasAuthorship W2894495537A5051264386 @default.
• W2894495537 hasAuthorship W2894495537A5051875406 @default.
• W2894495537 hasAuthorship W2894495537A5051915476 @default.
• W2894495537 hasAuthorship W2894495537A5052604055 @default.
• W2894495537 hasAuthorship W2894495537A5061217494 @default.
• W2894495537 hasAuthorship W2894495537A5065562779 @default.
• W2894495537 hasAuthorship W2894495537A5084123217 @default.
• W2894495537 hasAuthorship W2894495537A5084194739 @default.
• W2894495537 hasBestOaLocation W28944955371 @default.
• W2894495537 hasConcept C126322002 @default.
• W2894495537 hasConcept C159110408 @default.
• W2894495537 hasConcept C1862650 @default.
• W2894495537 hasConcept C187212893 @default.
• W2894495537 hasConcept C197934379 @default.
• W2894495537 hasConcept C203014093 @default.
• W2894495537 hasConcept C2777704310 @default.
• W2894495537 hasConcept C2778616394 @default.
• W2894495537 hasConcept C2779951463 @default.
• W2894495537 hasConcept C2780868878 @default.
• W2894495537 hasConcept C535046627 @default.
• W2894495537 hasConcept C71924100 @default.
• W2894495537 hasConcept C8891405 @default.
• W2894495537 hasConceptScore W2894495537C126322002 @default.
• W2894495537 hasConceptScore W2894495537C159110408 @default.
• W2894495537 hasConceptScore W2894495537C1862650 @default.
• W2894495537 hasConceptScore W2894495537C187212893 @default.
• W2894495537 hasConceptScore W2894495537C197934379 @default.
• W2894495537 hasConceptScore W2894495537C203014093 @default.
• W2894495537 hasConceptScore W2894495537C2777704310 @default.
• W2894495537 hasConceptScore W2894495537C2778616394 @default.
• W2894495537 hasConceptScore W2894495537C2779951463 @default.
• W2894495537 hasConceptScore W2894495537C2780868878 @default.
• W2894495537 hasConceptScore W2894495537C535046627 @default.
• W2894495537 hasConceptScore W2894495537C71924100 @default.

• next